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PRELIMINARY RESULTS OF PHASE II TRIAL OF CLOFARABINEWITH PAR-
ENTERAL BUSULFAN (CLO/BU) FOLLOWED BY ALLOGENEIC RELATED
OR UNRELATED DONOR TRANSPLANTATION FOR THE TREATMENT OF
HEMATOLOGIC MALIGNANCIES
Agura, E.1,2, Berryman, R.B1,2, Luis, P.1,2, Estil, V.1,2, Tadic-
Ovcina,M.1,Woelfel, R.1, Fay, J.1,2 1Charles A Sammons Cancer Center,
Baylor University Medical Center, Dallas, TX; 2Texas Oncology P.A.,
Dallas, TX
Background: RIT regimens are now common, but relapse remains
a problem. To address this issue, we proposed and tested a ‘‘mid-in-
tensity’’ conditioning regimen using clofarabine (CLO) with busul-
fan (BU). We hypothesized that this combination would be well
tolerated and offer greater anti-leukemic efficacy than existing RIT
regimens.
Methods:We enrolled 20 patients on this IST, with AML(10), ALL
(1), CLL (1), MDS (2) and MDS-AML (6). 15 patients had prior
therapies. The conditioning was: CLO 40 mg/m2 iv daily x5, BU
3.2 mg/kg iv daily x2, followed by 1 rest day, followed by HSCT.
Donors were matched at A, B, C, DR and DQ using DNA SBT or
mid-res DNA typing. Mismatch# 1 antigen was allowed. GVHD
prophylaxis was Tacrolimus and MTX 5 mg/m2 iv.
Results: Endpoints included toxicity, incidence/severity of
AGVHD, and disease response.
Grade 4 hem toxicity occured in all patients. GCSF was used in
18 of 20 subjects. The median time to recovery of ANC was 15
days (d9 – d17). Donor engraftment (.80% donor chimerism at
d30) occurred in all patients by FISH and/or STR. 2 patients
had hand/foot syndrome (1 Gr. 3, related); 1 respiratory failure
(Gr. 3 possibly related) resolved completely; 1 patient had elevated
ALT/AST (Gr.4, related) which resolved once regimen completed;
other toxicities were #Gr. 2. There were no transplant related
mortalities.
AGVHD occurred in 15 patients within the first 100 days. Of
these, 80%were grade 1-2 and 20% grade 3-4. There were no deaths
attributed to AGVHD following the study regimen.
The disease responses are: 10 (56%) patients, refractory(4), in re-
lapse (1), active disease (5) prior to initiation of CLO/BU, achieved
CR by d30. 7 (39%) patients who were in CR at study entry, remain
so at d30. 2 patients were N/E for disease response at d30. One pa-
tient (w/CLL) acheived CR at d132. 4 (22%) patients relapsed. 9
(45%) patients expired from: cardiac arrest (1, d316); aspergillus
pneumonia (1, d158); TTP (1, d438); AGVHD – post DLI (1,
d175); relapse (4, d222 median); MSOF (1, d91). Of 18 evauable pa-
tients, 10 (55%) remain in remission with a median follow up of 401
days.
Conclusions: CLO/BU is a mid-intensity allo HSCT regimen
with promising antileukemic efficacy that seems to be well toler-
ated without significant cardiac, renal or pulmonary toxicities.
Furthermore, CLO/BU resulted in full donor engraftment by
day 30 in all patients. Enrolment is closed; collection of data is
ongoing.329
EVALUATION OF BUSULFAN’S DOSE-INTENSITY IN PATIENTS UNDERGO-
ING ALLOGENEIC STEM CELL TRANSPLANTATION (ASCT) WITH TWO
DIFFERENT FLUDARABINE/BUSULFAN/ATG (FBA)-BASED REDUCED IN-
TENSITY CONDITIONING (RIC) REGIMENS
Hamadani, M.1, Craig, M.1, Abraham, J.1, Tse, W.1, Cumpston, A.1,
Stotler, C.J.1, Remick, S.C.1, Bunner, P.1, Leadmon, S.1, Elder, P.2,
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We evaluated the effects of busulfan’s dose-intensity in patients
undergoing RIC ASCT at two different transplant centers. Forty-
three patients were conditioned with busulfan (0.8 mg/kg/dose IV
 8 doses), fludarabine (30 mg/m2/day, days -7 to -3), and 6 mg/
kg of ATG (L-FBA), while 23 patients received a ‘more-intense’
RIC with busulfan (130 mg/m2/day IV, days -6 to -3), fludarabine
(40 mg/m2/day, days -6 to -3), and 6 mg/kg of ATG (H-FBA).
Median age was 55 years. 84% (N5 56) had high-risk disease. 19patients (29%) received mismatched allografts. 55 patients (83%)
received grafts from unrelated donors. Baseline characteristics
were well balanced between the two cohorts, except for higher pro-
portion of unrelated donors in L-FBA group (p-value5 0.02). All
patients engrafted neutrophils and platelets (median 17 and 13
days, respectively). There were no graft rejections. Compared to
patients receiving H-FBA, those receiving L-FBA had fewer
CMV reactivations (48% vs. 30%; p-value5 0.15), bacterial infec-
tions (69% vs. 43%; p-value5 0.004) and slightly lower rates of
1-year non-relapse mortality (17% vs. 7%; p-value5 0.19). Com-
pared to L-FBA, H-FBA did not reduce relapse rates (34% vs.
43%; p-value5 0.49). Rate of grade II-IV acute GVHD (30% vs.
52%; p-value5 0.08) favored L-FBA, while incidence rate of
chronic GVHD (40% vs. 40%; p-value5 0.11) were similar. Me-
dian day +90 and +360 chimerism for both groups was 100%. 38
patients (58%) were in CR after ASCT. The median follow-up
of surviving patients is 12 months. Compared to patients receiving
H-FBA, ones receiving L-FBA showed a significantly superior
1-year overall survival (44% vs. 68% p-value5 0.02) and trend
toward improved 1-year progression free survival (33% vs. 60%
p-value5 0.07). Our preliminary, retrospective data suggests that
L-FBA maintains acceptable rates of disease relapse, non-relapse
mortality, full-donor cell chimerism and GVHD control compared
to H-FBA, and may be associated with lower rates of infectious
complications and improved survival.330
INFLUENCE OF COMORBIDITIES ON TRANSPLANT OUTCOMES IN PA-
TIENTS AGED 50 YEARS OR MORE AFTER MYELOABLATIVE CONDITION-
ING INCORPORATING FLUDARABINE, BUSULFAN AND ATG
Elkourashy, S.A.1, Yang, M.1, Turner, R.2, Larratt, L.M.2,
Brown, C.B.1, Bahlis, N.J.1, Savoie, L.M.1, Daly, A.1, Geddes, M.1,
Storek, J.1, Zacarias, N.1, Duggan, P.R.1, Quinlan, D.2, Stewart, D.1,
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Non-myeloablative (NST) and reduced intensity (RIC) regimens
are offered to older patients (pts) and/or those with comorbidities
because the morbidity and mortality attributable to fully myeloabla-
tive conditioning is thought to be unacceptably high. All such pa-
tients receive myeloablative protocols in our program, outcomes
have been analyzed in order to determine whether this practice is jus-
tifiable. Between 1999 and 2008 207 patients (pts) with hematologic
malignancy aged 50–66 years (median 56) received blood cell (87%)
or marrow transplants after conditioning with Flu 50 mg/m2 daily
5 and IV Bu 3.2 mg/kg daily 4. 90 (43%) had additional total body
irradiation (TBI) 200 cGy  2. Graft-versus-host disease (GVHD)
prophylaxis was cyclosporin A, methotrexate and Thymoglobulin
(Genzyme) 4.5 mg/kg total dose. Donors were matched siblings in
125 (60%) mismatched related in 11 (5%), 10/10 matched unrelated
in 54 (26%) and mismatched unrelated in 17(8%). 74 pts (36%) had
low-risk (LR, acute leukemia CR1/CR2, CML CP1) disease. As de-
fined by the HCT-CI scoring system 117 (57%) pts scored 0 (low
HCT-CI), 68 (33%) 1 or 2 (intermediate HCT-CI) and 22 (11%,)
$3 (highHCT-CI). Transplant risk factors were similar between in-
termediate and high HCT-CI groups. As NRM (33% and 33% vs
24% and 48%, p5 ns) and DFS (46% and 37% vs 64% and 43%,
p5 ns) at 1 and 5 years respectively were also similar, outcomes in
these 2 groups were combined for more robust analysis. The propor-
tion of pts with LR disease was higher in those with comorbidities
(intermediate and high HCT-CI) (49% vs 26%, p5 0.0006) than
those without. OS was 56% and 39% vs 74% and 54%
(p5 0.008), DFS 50% and 38% vs 68% and 49% (p5 0.03),
NRM 31% and 39% vs 15% and 19% (p5 0.003) and relapse
26% and 36% vs19% and 39% (p5 ns) respectively at 1 and 5 years.
In 48 AML pts in CR1&CR2, 27 (56%) with comorbidities, receiv-
ing this protocol with TBI DFS at 5 years was 66%. We conclude
that: 1. Comorbidities influence NRM with this regimen although
cannot confirm that the high HCT-CI group is at higher risk than
the intermediate. 2. Age alone should not be an indication to prefer
a less intense protocol particularly in a condition such as AMLwhere
there is an effect of regimen intensity on relapse. 3. Although NRM
